Malin raises up to 330 million euros; to list on Irish Stock Exchange

20 March 2015

Malin Corporation, a newly-incorporated Irish-based global life sciences company, says it has raised up to 330 million euros ($347 million) made up of committed gross proceeds and additional investment commitments. Malin also said it will list on the ESM of the Irish Stock Exchange on March 25, 2015.

Malin has already identified and entered into acquisition and investment agreements or binding heads of agreement with seven operating companies (listed below), which meet its criteria, and has total committed expenditure in respect of these companies of around 100 million euros with a further amount of up to about 130 million euros of follow-on investment options or investments subject to contingent commitments. Malin will also seek to make a number of further acquisitions and investments post its flotation.

Assets to be acquired

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical